Mesenchymal Stem Cells for Treatment of ARDS Following Trauma
Abstract
The acute respiratory distress syndrome (ARDS) is a life-threatening medical condition in which the lung is injured orinflamed to the degree that it cannot properly exchange gases and oxygenate the body. ARDS can be caused by a variety ofconditions including trauma, severe blood loss, multiple or large volume blood transfusions, burns, and infections. Thedevelopment of therapeutics that can limit the severity and/or progression of lung injuries that lead to ARDS and death is animmediate clinical need in both military and civilian sectors. Experimental studies carried out in small and large animals havedemonstrated that specialized cells called mesenchymal stromal cells (MSC) can effectively reduce inflammation in multiplediseases including ARDS. The overall objective of this proposal is to carry out a randomized, blinded, placebo-controlled,multicenter phase 2b trial to test the therapeutic potential of allogeneic bone-marrow derived MSC for treating ARDS, with amajor focus on civilian trauma patients. The specific aims of this project are: Specific Aim 1. To test the clinical efficacy ofintravenously delivered allogeneic human MSC in patients with ARDS. Specific Aim 2. To test the mechanisms by whichMSC reduce acute lung injury in trauma patients with ARDS.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2019
- Accession Number
- AD1092050
Entities
People
- Michael A. Matthay
Organizations
- University of California, San Francisco